PEA for Senior Dogs: What the Research Says

Watching a dog grow older can be bittersweet. The gray muzzle is charming, but stiffness, slower movement, and difficulty getting comfortable are harder to accept.

These changes have led many senior dog owners to explore palmitoylethanolamide, usually shortened to PEA. Although the name sounds complicated, PEA is a naturally occurring fatty compound made by the bodies of dogs, people, and other mammals.

Researchers are studying supplemental PEA for its potential to support comfort and help regulate the body’s response to physical stress. Early results are encouraging, particularly for dogs experiencing joint discomfort, but it is important to understand what the research does and does not prove.

What Is Palmitoylethanolamide?

PEA is a fatty acid amide produced naturally by cells throughout the body. It is sometimes described as an “endocannabinoid-like” compound, but it is not marijuana, CBD, or an intoxicating substance.

The body appears to produce PEA in response to irritation, injury, or cellular stress. One of its best-studied actions involves a receptor called PPAR-alpha. This receptor helps regulate inflammatory signals and the way certain immune cells respond to stress.

In plain English, PEA appears to act as part of the body’s built-in system for restoring balance when tissues become irritated or overstimulated.

Supplemental PEA is intended to reinforce this natural process. It should not be confused with pea protein, even though both are commonly abbreviated as “PEA.”

How Might PEA Benefit Senior Dogs?

Supporting Joint Comfort and Mobility

Joint comfort is currently one of the most promising areas of PEA research in dogs.

In a 2026 double-blind, randomized, placebo-controlled study, researchers evaluated 50 dogs experiencing joint pain. The average age of the dogs was approximately 10 years, making the results particularly relevant to senior dog owners.

After six weeks:

• 76% of dogs receiving a formulated version of PEA met the study’s definition of successful treatment.

• 40% of dogs receiving the placebo met the same standard.

• Dogs receiving PEA showed improvements in several measures of discomfort and daily function.

• Owners reported improvements in activities such as rising from a lying position, walking, running, and general activity.

Some functional improvements appeared by the second week, while clearer differences in discomfort were generally seen after four to six weeks.

These findings are encouraging, but the study had limitations. It was relatively small, relied heavily on owner observations, and was funded by the manufacturer of the PEA ingredient being tested.

It is therefore reasonable to say that PEA may support joint comfort and everyday mobility, but not that it has been proven to treat the underlying cause of joint problems or replace veterinary care.

Helping Maintain a Healthy Inflammatory Response

Inflammation is not automatically harmful. It is part of the body’s normal response to injury and other physical challenges. Problems can develop, however, when inflammatory signals remain active longer than needed.

Laboratory research suggests that PEA helps regulate several cells and signaling pathways involved in this process. Its activity at the PPAR-alpha receptor appears to be especially important.

PEA has also been studied in laboratory models of joint discomfort. In one study, a formulation combining PEA with quercetin improved movement and reduced signs of discomfort in rats with experimentally induced joint problems.

Human evidence provides additional support. In a randomized, placebo-controlled trial involving 111 adults with mild to moderate knee discomfort, daily PEA improved several measures of comfort and joint function over eight weeks.

Results in people and laboratory animals cannot automatically be applied to dogs. Together with the newer canine trial, however, these findings strengthen the case for continued research into PEA as nutritional support for physical comfort.

Supporting Skin Comfort

Some of the earliest PEA research in dogs focused on itchy, irritated skin.

In a multicenter study, 160 dogs with ongoing skin irritation received ultra-micronized PEA for eight weeks. Researchers reported reductions in itching and visible skin irritation, along with improvements in quality-of-life scores.

This was an open-label study, meaning that everyone knew the dogs were receiving PEA and there was no placebo group. That makes it difficult to determine exactly how much of the improvement resulted from PEA itself.

Laboratory research using canine skin cells provides additional context. PEA reduced the release of histamine and other inflammatory compounds from canine mast cells. Mast cells are immune cells involved in itching and skin reactions.

These findings suggest that PEA may help support normal skin comfort. However, itching in an older dog can have many possible causes. Persistent itching, sores, hair loss, or changes in the skin deserve a veterinary examination rather than treatment with supplements alone.

Possible Support for the Aging Nervous System

PEA is also being investigated for its possible effects on nerve cells, oxidative stress, and age-related changes in the brain.

In one study involving mice with experimentally produced changes in brain function, three months of oral PEA improved cognitive performance and reduced laboratory signs of neuroinflammation and oxidative stress.

This is interesting research, but it is still early. Results from a laboratory mouse model cannot be assumed to occur in naturally aging dogs.

At present, there is not enough direct canine research to claim that PEA prevents or treats age-related changes in canine behavior or mental function. Changes such as nighttime restlessness, confusion, staring, house-soiling, or altered social behavior should be discussed with a veterinarian.

Is PEA Safe for Dogs?

PEA has generally been well tolerated in published studies.

In the six-week canine joint study, no adverse events were reported among the dogs receiving PEA. The larger canine skin study also described the tested PEA formulation as well tolerated.

That does not mean every PEA product is appropriate for every dog. Safety can depend on:

• The amount provided

• The specific formulation

• Other ingredients in the product

• The dog’s weight and overall health

• Medications or supplements the dog already receives

A veterinarian should be consulted before adding PEA for a dog with a serious health concern, unexplained discomfort, significant mobility loss, or an extensive medication schedule.

PEA should also be viewed as supportive nutrition, not as a replacement for prescribed medication. Never stop or reduce a dog’s medication without speaking with the prescribing veterinarian.

Are All PEA Supplements the Same?

Not necessarily.

PEA does not dissolve easily in water and may be absorbed differently depending on how it is prepared. Researchers have used micronized, ultra-micronized, and other formulated versions intended to improve absorption.

Products can also vary widely in the amount of PEA they provide. Owners should look for a clearly stated amount rather than relying on a vague “proprietary blend.”

It is also important to remember that research performed on one particular formulation does not automatically prove that every PEA supplement will produce identical results.

PEA is available by itself and as part of combination products. For example, Amiquip combines PEA with PQQ in a soft chew designed to support comfort and healthy aging in senior dogs.

What Results Should Owners Expect?

PEA is not a fast-acting rescue medication. Based on the available canine joint study, some changes in everyday function may become noticeable within a few weeks, while comfort-related differences may take four to six weeks.

Useful changes to watch for include:

• Getting up more easily

• Greater willingness to walk

• Less hesitation on stairs

• More interest in normal activities

• Improved ability to settle and rest

• Less licking or chewing at irritated skin

Keeping brief weekly notes can make gradual changes easier to recognize. It can also help owners and veterinarians decide whether a supplement is providing meaningful value.

The Bottom Line

PEA is a naturally occurring compound involved in the body’s response to physical and inflammatory stress.

The strongest direct evidence in dogs currently suggests that certain PEA formulations may support:

• Joint comfort

• Mobility and everyday function

• A healthy inflammatory response

• Skin comfort

The research is promising, but still developing. PEA has not been proven to reverse aging or correct the underlying causes of discomfort and age-related changes.

For many older dogs, it may be a useful part of a broader healthy-aging plan that also includes veterinary care, weight management, suitable exercise, good nutrition, comfortable flooring, and appropriate medication when needed.

References

1. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-9. doi:10.1124/mol.104.006353.

2. Briskey D, Craddock E, Rao A, Mills PC. Levagen+ (palmitoylethanolamide) alleviates joint pain and reduces the impact of joint pain in canines and felines: a double-blind, placebo-controlled, randomized clinical trial. Front Vet Sci. 2026;13:1703143. doi:10.3389/fvets.2026.1703143.

3. Britti D, Crupi R, Impellizzeri D, Gugliandolo E, Fusco R, Schievano C, et al. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. BMC Vet Res. 2017;13:229. doi:10.1186/s12917-017-1151-z.

4. Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-85. doi:10.1007/s10787-019-00582-9.

5. Noli C, della Valle MF, Miolo A, Medori C, Schievano C; Skinalia Clinical Research Group. Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Vet Dermatol. 2015;26(6):432-e101. doi:10.1111/vde.12250.

6. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNF-alpha release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133(1):9-15. doi:10.1016/j.vetimm.2009.06.011.

7. Beggiato S, Tomasini MC, Cassano T, Ferraro L. Chronic oral palmitoylethanolamide administration rescues cognitive deficit and reduces neuroinflammation, oxidative stress, and glutamate levels in a transgenic murine model of... J Clin Med. 2020;9(2):428. doi:10.3390/jcm9020428.